2-(2,3-dicarboxycyclopropyl)glycine has been researched along with quinolinic acid in 1 studies
| Studies (2-(2,3-dicarboxycyclopropyl)glycine) | Trials (2-(2,3-dicarboxycyclopropyl)glycine) | Recent Studies (post-2010) (2-(2,3-dicarboxycyclopropyl)glycine) | Studies (quinolinic acid) | Trials (quinolinic acid) | Recent Studies (post-2010) (quinolinic acid) |
|---|---|---|---|---|---|
| 166 | 0 | 27 | 1,856 | 19 | 472 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cano, J; Machado, A; Rite, I; Venero, JL | 1 |
1 other study(ies) available for 2-(2,3-dicarboxycyclopropyl)glycine and quinolinic acid
| Article | Year |
|---|---|
Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Corpus Striatum; Cyclopropanes; Denervation; Disease Models, Animal; Down-Regulation; Female; Glutamate Decarboxylase; Glycine; Huntington Disease; N-Methylaspartate; Neural Pathways; Neurons; Neurotoxins; Proto-Oncogene Proteins c-fos; Quinolinic Acid; Rats; Rats, Wistar; Receptor, trkB; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase | 2005 |